Thus, regardless of the mechanisms by which disulfiram attenuated experimental AAAs, our findings together with those from other recent studies suggest that pharmacologically inhibiting gasdermin D may have the translational application for limiting clinical AAA progression. The gene discussed is GSDMD; the disease is achalasia-alacrima syndrome.